title: Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.
abstract: BACKGROUND
  Many African Americans carry an amyloidogenic transthyretin mutation (TTR V122I), with a high risk for cardiac TTR amyloid deposition after the age of 65 years. We wished to determine the allele frequency and its clinical penetrance in community-dwelling African Americans.
  
  
  METHODS
  Five thousand consenting African Americans, aged 41 to 93 years, in 2 community studies of cardiovascular risk (CHS and ARIC) were included in the study. The following were performed: genotyping of banked DNA for TTR V122I allele status and review of cardiovascular and demographic parameters in CHS and ARIC databases, with statistical comparisons of the frequency of congestive heart failure, survival, and occurrence of features of cardiac amyloidosis in carriers of the amyloidogenic allele and controls.
  
  
  RESULTS
  One hundred nineteen (3.23%) of 3,712 ARIC and 17 (2.12%) of 805 CHS African Americans carried TTR V122I. After the age of 65 years (CHS), the frequencies of congestive heart failure (38% vs 15%, relative risk 2.62, P = .04) and mortality (76% vs 53%, relative risk 1.46, P = .08) were higher in V122I allele carriers than in age-, gender- and ethnically matched controls. In ARIC (all subjects <65 years old), there were no differences between carriers and noncarriers in mortality, frequency of congestive heart failure, or findings consistent with cardiac amyloidosis.
  
  
  CONCLUSIONS
  Heterozygosity for the amyloidogenic TTR V122I mutation is relatively common in community-dwelling African Americans. Before the age of 65 years, the allele has no discernible impact on cardiac function or mortality. After the age of 70 years, carriers show a higher frequency of congestive failure and greater mortality with more echocardiographic evidence suggestive of cardiac amyloidosis, findings consistent with age-dependent clinical penetrance of this autosomal dominant gene.
authors.affiliation: The Scripps Research Institute, La Jolla, CA 92037, USA. jbux@scripps.edu
authors.forename: Joel
authors.initials: J
authors.lastname: Buxbaum
authors.forename: Alice
authors.initials: A
authors.lastname: Alexander
authors.forename: James
authors.initials: J
authors.lastname: Koziol
authors.forename: Clement
authors.initials: C
authors.lastname: Tagoe
authors.forename: Ervin
authors.initials: E
authors.lastname: Fox
authors.forename: Dalane
authors.initials: D
authors.lastname: Kitzman
mesh_terms: D000328:Adult; D001741:Black or African American / Q000235:genetics*; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000000981:diagnostic imaging / Q000208:ethnology / Q000235:genetics* / Q000401:mortality; D005260:Female; D005787:Gene Frequency; D006331:Heart Diseases / Q000000981:diagnostic imaging / Q000208:ethnology / Q000235:genetics* / Q000401:mortality; D006801:Humans; D007532:Isoleucine / Q000235:genetics; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011228:Prealbumin; D014463:Ultrasonography; D014633:Valine / Q000235:genetics
chemical_list: D011228:Prealbumin; D007532:Isoleucine; D014633:Valine